Protein C: Nursing Guide
Protein C is a vitamin K–dependent natural anticoagulant that, with protein S, slows thrombin generation by inactivating factors VIIIa and Va. Nurses support thrombophilia workups by protecting citrate specimen quality, documenting warfarin and acute-VTE timing, and escalating new leg swelling or chest pain clinically — not waiting for send-out coagulation results.
Contents
Quick Facts
Key Takeaway
Low protein C activity raises lifetime venous thromboembolism risk but does not diagnose an active clot today — and acute thrombosis, warfarin, liver disease, pregnancy, and DIC can temporarily lower levels until.
Specimen & Collection Details
Nurse quick-reference for collection prep that affects result quality.
Light blue top
3.2% sodium citrate (9:1 blood-to-anticoagulant ratio)
Platelet-poor plasma (citrated)
Tube filled to completion per coagulation protocol; follow laboratory minimum volume for platelet-poor plasma
Not for at least 10 days after a thrombotic episode and not while on anticoagulant therapy per reviewed references; usually after acute VTE is treated and the patient is clinically stable — follow local thrombophilia policy
No test preparation is usually required
Double-centrifuge to platelet-poor plasma, aliquot to plastic vial, freeze per institutional coagulation handling — not routine room-temperature transport
Typically days (referral coagulation laboratory)
Coagulation / specialized hemostasis laboratory
What is Protein C?
Protein C measures functional protein C activity in plasma (often reported as a percentage of normal) and, when ordered, protein C antigen quantity. Protein C is synthesized in the liver and requires vitamin K; after activation by the thrombin–thrombomodulin complex, it works with protein S to degrade activated factors VIII and V, slowing clot formation.
Overview
Nurses most often encounter protein C testing during thrombophilia panels after unexplained deep vein thrombosis, pulmonary embolism, unusual-site venous thrombosis, neonatal purpura fulminans workups, or family history of severe protein C deficiency. Activity assay is usually the first step; if activity is low, antigen testing helps distinguish Type I (low quantity) from Type II (dysfunctional protein).
Because protein C is consumed during acute thrombosis and lowered by warfarin, liver disease, DIC, pregnancy, and asparaginase therapy, results must be interpreted with timing and medication history. Repeat testing after recovery and off interfering anticoagulants is commonly required before confirming lifelong hereditary deficiency.
Before collection, confirm the indication matches thrombophilia protocol timing, verify the patient is not actively clotting on heparin-contaminated lines, use a completely filled citrate tube with gentle mixing, and document recent VTE, anticoagulants, pregnancy, and liver or kidney disease. Escalate new or worsening leg swelling, chest pain, or shortness of breath according to facility policy — do not wait for the send-out result.
Warfarin Timing and Protein C Specimen Safety
Protein C results guide long-term thrombosis risk conversations, but warfarin, acute VTE, and poor citrate technique can falsely lower activity and trigger unnecessary lifelong labels. Never delay assessment of new leg swelling, chest pain, or dyspnoea while waiting for send-out coagulation results.
- Acute VTE symptoms with pending or low protein C — escalate clinically first
- Testing within 10 days of thrombosis or on anticoagulants without authorized hold and repeat plan
- Interpreting a single low activity as confirmed hereditary deficiency without antigen testing and repeat sampling
- Starting warfarin in known severe deficiency without haematology input — monitor per specialist protocol
Document: indication and timing criteria met, tube fill and processing, warfarin and anticoagulant holds, clinical VTE symptoms, result with reference interval, notifications, and repeat or genetics plan.
What Protein C Activity Can and Cannot Tell You
This test can help identify:
- Reduced functional protein C suggesting Type I or II deficiency when appropriately timed
- Acquired protein C consumption in DIC, liver disease, pregnancy, or recent thrombosis
- Need for antigen testing, repeat sampling, or genetics after a confirmed low activity
- Combined thrombophilia risk when paired with factor V Leiden, prothrombin mutation, or lupus anticoagulant results
This test cannot:
- Diagnose acute deep vein thrombosis or pulmonary embolism by itself — use acute VTE pathways
- Replace clinical assessment, imaging, or D-dimer protocols where indicated
- Confirm hereditary deficiency from one sample during acute illness or on anticoagulants
- Determine anticoagulation duration or hormone choices alone — requires specialist decisions
Citrate Collection and Anticoagulant Holds Before Protein C Draw
Verify
Clarify before proceeding when:
- Order is routine on acute admission without thrombophilia timing criteria
- Patient still on warfarin, heparin, or DOAC without authorized hold window
- Less than 10 days since thrombotic episode per institutional protocol
- Prior specimen rejected for underfill, hemolysis, or clot
- Active unilateral leg swelling, chest pain, or dyspnoea is present
- Central line draw may contain heparin flush and policy requires peripheral draw
- Result conflicts with strong family history but sample timing was during acute DVT only
Type I vs Type II Deficiency and Vitamin K Effects
Pair protein C activity with timing after VTE, warfarin and anticoagulant holds, antigen results, protein S, antithrombin III, lupus anticoagulant, and factor V Leiden where ordered, pregnancy plans, and current symptoms. Repeat testing after recovery and off interfering drugs is commonly required.
| Clinical context | Pair with protein C | Nursing focus |
|---|---|---|
| Post-VTE thrombophilia screen | Low activity + low antigen → Type I pattern | Support genetics referral and family screening per haematology |
| Low activity, normal antigen | Suggests Type II dysfunctional protein | Do not reassure based on activity alone; confirm with specialist interpretation |
| Recent warfarin therapy | Transiently low protein C possible | Document hold interval; repeat when off vitamin K antagonists per protocol |
| Neonatal purpura fulminans | Very low or absent protein C activity | Escalate urgently per neonatal protocol; specialist replacement may be required |
Protein C Traps at the Bedside
| Bedside point | Nursing note |
|---|---|
| 10-day rule | Do not collect within 10 days of thrombosis or on anticoagulants without protocol clearance |
| Warfarin trap | Vitamin K antagonists lower protein C — timing after warfarin stop is essential for valid hereditary testing |
| Tube fill | Underfilled citrate is a frequent reject — fill to the line and mix gently ×6 |
| Not a stat VTE test | Send-out protein C does not rule in or out PE today — escalate symptoms clinically |
| Confirm before labeling | One low result needs antigen and repeat off anticoagulants — avoid premature “clot gene” language |
| Homozygous neonatal risk | Purpura fulminans in a newborn is an urgent escalation pathway — not routine outpatient timing |
Thrombophilia Panel Workflow With Protein C
Diagnostic safety badge: Routine diagnostic test — standard identification, preparation, and result-follow-up checks still apply; low results may require confirmatory testing and specialist follow-up.
Check-before-test protocol
- Identity + indication + thrombophilia timing criteria (≥10 days post-event, off anticoagulants)
- Warfarin and anticoagulant hold authorized and documented
- Citrated tube supply and processing steps confirmed
- Clinical VTE symptom screen
- Requisition clinical history completed
Critical teach-back questions
- “Can you tell me why we are checking your protein C level now rather than during your hospital clot treatment?”
- “What new leg or chest symptoms should you report before the result comes back?”
- “Why might the team repeat this blood test after you finish anticoagulation?”
Care coordination: prescriber, haematology, laboratory/coagulation services, genetics service when indicated, anticoagulation clinic, and rapid response per institutional protocol.
Why Protein C is Ordered
Protein C testing is ordered when clinicians evaluate inherited or acquired protein C deficiency as part of a hypercoagulability workup — typically after VTE is treated and the patient is stable, not as a routine screen for every clot.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Unexplained venous thromboembolism in a relatively young patient | Is a high-risk thrombophilia such as protein C deficiency present? | Part of thrombophilia screening after appropriately timed sampling when results may change long-term anticoagulation or prophylaxis decisions. |
| Family history of protein C or protein S deficiency | Does selective family screening apply per haematology or genetics protocol? | Relatives may be tested when a severe deficiency or very early VTE occurred in the family — not as routine population screening per reviewed references. |
| Neonatal purpura fulminans or severe clotting in a newborn | Could homozygous protein C deficiency require urgent specialist care? | Homozygous deficiency can cause life-threatening neonatal purpura fulminans or DIC — nurses escalate per neonatal and haematology protocol while testing is pending. |
| Unusual-site venous thrombosis (cerebral, splanchnic, renal veins) | Should long-term management consider severe thrombophilia? | Selected scenarios support thrombophilia evaluation when results may influence duration of anticoagulation or hormone-therapy counseling. |
Contraindications and Precautions
There is no absolute laboratory contraindication, but nurses must not proceed with routine thrombophilia sampling when timing or specimen integrity would produce misleading results.
- Testing within 10 days of acute thrombosis or during active anticoagulant therapy without protocol authorization — protein C may be consumptively or iatrogenically low.
- Ongoing warfarin, heparin, or direct oral anticoagulant without hold per laboratory policy.
- Underfilled citrate tube, hemolyzed sample, or failure to obtain platelet-poor plasma.
- Liver disease, vitamin K deficiency, DIC, sepsis, pregnancy, renal disease, and malignancy.
- Warfarin and other vitamin K antagonists reduce protein C along with other clotting factors.
- A single borderline low value should prompt repeat testing after recovery, not immediate lifelong diagnosis without confirmation.
- New or worsening unilateral leg swelling, pain, warmth, or redness while awaiting results.
- Acute chest pain, dyspnoea, tachycardia, or hypoxia suggesting pulmonary embolism.
- Confirmed very low protein C with acute thrombosis signs — notify prescriber and haematology per protocol; evaluate outcomes of anticoagulation and prophylaxis plans.
Patient Preparation
No special patient preparation is usually required for protein C testing, but thrombophilia protocols require specific timing relative to acute clots and anticoagulants.
Pre-test checksReview warfarin and other vitamin K antagonists, unfractionated heparin, low-molecular-weight heparin, direct oral anticoagulants, and oestrogen-containing contraceptives or HRT. Do not stop prescribed anticoagulation without prescriber authorization — clarify hold timing with the ordering clinician and laboratory.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Protein C. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
Protein C activity is commonly reported as a percentage of the laboratory reference population. Decreased activity suggests deficiency; normal activity makes hereditary deficiency unlikely per reviewed references. Antigen testing and repeat sampling clarify Type I vs Type II patterns.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Within expected range or therapeutic target | Within institutional reference interval (activity % or antigen) | Functional protein C adequate at time of sample | If part of thrombophilia panel, interpret with other results; hereditary deficiency unlikely if activity normal |
| Near therapeutic target / borderline | Borderline low or discordant activity vs antigen | May reflect assay variation, pre-analytic error, warfarin effect, or evolving acquired state | Recommend repeat testing per haematology protocol after appropriate interval and medication review |
| Prolonged / above target | Elevated protein C activity or antigen | Not usually clinically significant when function is normal per reviewed references | Interpret with clinical context; not a typical thrombosis escalation trigger alone |
| Shortened / below target | Below reference interval (decreased activity or antigen) | Possible Type I or II deficiency, acquired consumption, warfarin effect, or liver disease | Notify prescriber; arrange antigen assay and repeat testing off anticoagulants per protocol; genetics referral if confirmed |
Protocol targets, critical results and escalation
Universal numeric critical values for protein C are Turnaround and screening rules vary by institution; follow local institutional policy. Escalation is driven by clinical thrombosis risk, neonatal purpura fulminans, confirmed severe deficiency with symptoms, and warfarin initiation in known deficiency requiring specialist input.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Low protein C with acute VTE signs | Decreased activity plus new leg swelling, chest pain, or dyspnoea | Escalate according to facility policy; initiate acute VTE pathway per prescriber — do not delay for send-out results |
| Neonatal purpura fulminans or DIC pattern | Severe skin necrosis or consumptive coagulopathy in a newborn | Escalate urgently per neonatal and haematology protocol; protein C concentrate may be considered per specialist guidance |
| Specimen rejected / invalid | Hemolysis, clot, underfill, or heparin contamination | Repeat collection per coagulation policy before thrombophilia conclusions are made |
Stop routine workflow and escalate according to facility policy when the patient develops symptoms suggesting acute venous thromboembolism, when a critically low result is reported with haemodynamic compromise, or when results conflict strongly with the clinical picture.
Factors Affecting Results
Protein C assays are sensitive to pre-analytic variables, vitamin K status, and concurrent illness. Nurses prevent misinterpretation with correct citrate technique and documented context.
- Falsely low activity during acute thrombosis, surgery, or DIC consumption
- Warfarin or vitamin K deficiency lowering protein C before other factors normalize
- Underfilled citrate tube altering anticoagulant ratio
- Falsely normal activity during intercurrent illness without repeat confirmation
- Single test on anticoagulant therapy masking hereditary deficiency until repeat off therapy
- Assuming normal activity rules out all thrombophilia — other defects may coexist
- Timing relative to acute VTE (minimum interval per protocol)
- Warfarin, heparin, liver disease, pregnancy, DIC, asparaginase
- Specimen quality — hemolysis, platelets, delayed processing
Protein C testing alone does not diagnose active thrombosis and cannot replace clinical probability assessment. Broad thrombophilia testing is not recommended in many VTE scenarios when results would not change management; nurses support appropriate ordering and timing. Reference ranges, critical thresholds, and repeat intervals vary by laboratory and method.
Nursing Responsibilities
Nursing responsibilities emphasize correct coagulation specimen handling, warfarin and timing documentation, symptomatic monitoring while results are pending, and clear communication of low or unexpected values.
Before the TestDocumentation
Documentation should link specimen quality, clinical context, and communication of abnormal results.
“Protein C activity specimen collected 10:15 — light-blue citrate tube filled to line, inverted ×6, double-spun per lab policy, frozen aliquot to coagulation lab. Patient 12 weeks post-DVT treatment; rivaroxaban held 72 h per haematology. No acute leg pain today. Requisition notes family history of protein C deficiency. Activity 58% (below reference); antigen pending. Prescriber notified; patient taught symptom reporting.”
- Indication, order date, and thrombophilia protocol timing met (yes/no)
- Tube type, fill level, mixing, processing, and transport compliance
- Recent VTE, pregnancy, liver/renal disease, warfarin, and anticoagulant holds
- Result value with laboratory reference interval and flag status
- Prescriber/haematology notification and patient teaching provided
- Repeat specimen plan and genetics referral if ordered
Patient and Family Education
Patients often worry that a blood test predicts an immediate clot. Use clear language about what protein C measures and why timing after treatment matters.
Protein C NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Protein C safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: Protein C activity — plasma, thrombophilia panel
- Indication: 32-year-old with prior unprovoked DVT; family history of protein C deficiency
- Timing: Ordered today — 12 weeks after completing initial anticoagulation; warfarin stopped 8 weeks ago
- Related orders: Protein S, antithrombin III, lupus anticoagulant screen; factor V Leiden per protocol
- Result: Protein C activity 58% (below laboratory reference); prior draw during acute DVT was 41%
- Trend / prior value: Improved from acute phase but still below reference; antigen assay pending
- Pending tests: Protein C antigen, genetics referral discussion, repeat activity if hold window completed
- Vital signs: HR 76/min, BP 120/74, RR 16/min, SpO₂ 98% on room air, temp 36.8°C
- Symptoms: No current leg pain or dyspnoea; asks whether low protein C means another clot today
- Focused assessment: Calves symmetric, no tenderness; lungs clear; rivaroxaban held 72 h per haematology order
- Preparation notes: Citrated tube filled to line; patient asked why testing was delayed until after treatment
- Collection events: Earlier sample rejected for underfilled citrate tube; today’s specimen accepted
- Teaching gaps / safety concerns: Low activity not yet confirmed hereditary; patient unclear on symptom reporting; pending antigen
Answer key & rationale
Frequently Asked Questions
FAQ
Why is protein C tested after a blood clot instead of during the acute admission?
Acute thrombosis consumes protein C and anticoagulant therapy interferes with interpretation. Reviewed references state testing should not be requested for at least 10 days after a thrombotic episode and not while on anticoagulant therapy — usually after VTE is treated and the patient is stable. Follow local policy.
Does the patient need to fast before protein C testing?
No test preparation is usually required per reviewed references. Follow fasting instructions only if other ordered tests on the same draw require it.
What does a low protein C activity result mean?
It suggests reduced functional protein C, which may reflect inherited Type I or II deficiency or acquired causes such as liver disease, warfarin effect, DIC, or recent thrombosis. Antigen testing and repeat sampling help clarify. It does not by itself prove an active clot today.
Can warfarin affect protein C results?
Yes. Warfarin and other vitamin K antagonists lower protein C along with other vitamin K–dependent clotting factors. Testing is usually deferred until anticoagulant therapy is completed per thrombophilia protocol — do not stop prescribed anticoagulation without prescriber authorization.
Is protein C testing recommended for every patient with one DVT?
Not routinely. Guidelines conditionally recommend against broad thrombophilia testing in many VTE scenarios and support selective testing when results would change management — such as strong family history of protein C deficiency or very early unexplained VTE.
What tube is used for protein C activity?
Platelet-poor plasma from a light-blue-top tube with 3.2% sodium citrate, filled to the marked line, with gentle mixing and laboratory processing per coagulation protocol (often double-centrifuged and frozen for send-out testing).
When should nurses escalate before the result returns?
Escalate according to facility policy if the patient develops new unilateral leg swelling, pain, warmth, redness, chest pain, dyspnoea, tachycardia, or hypoxia — these may indicate acute VTE regardless of pending protein C results.
References
References
-
Association for Clinical Biochemistry and Laboratory Medicine. Protein C and Protein S. Lab Tests Online UK.https://labtestsonline.org.uk/tests/protein-c-and-protein-s
-
American Society of Hematology. 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023.https://pmc.ncbi.nlm.nih.gov/articles/PMC10709681/
-
Mayo Clinic Laboratories. Protein C Activity, Plasma. Rochester (MN): Mayo Clinic.https://www.mayocliniclabs.com/test-catalog/overview/8158
-
Labcorp. Protein C Activity — Test 117030. Burlington (NC): Labcorp.https://www.labcorp.com/tests/117030/protein-c-activity
-
Kujovich JL. Protein C deficiency. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.https://www.ncbi.nlm.nih.gov/books/NBK131845/
-
Kujovich JL. Hypercoagulability. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.https://www.ncbi.nlm.nih.gov/books/NBK538251/
-
National Library of Medicine. Protein C blood test. MedlinePlus.https://medlineplus.gov/lab-tests/protein-c-and-protein-s-blood-test/
-
Stevens SM; et al. Hypercoagulable states: an algorithmic approach to laboratory testing. Blood Rev. 2016.https://pmc.ncbi.nlm.nih.gov/articles/PMC4090343/
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Protein C.
Policies: Medical Review Process · Editorial Policy · Correction Policy